White House Projected Medicaid Drug Savings

The Council of Economic Advisers estimated $64.3 billion in savings over a decade through the GENEROUS program.

Updated on Oct. 7, 2026 in Healthcare

Bold flat-color editorial illustration of medicine vials in a grid, evoking the scale of national healthcare cost savings. — The White House Council of Economic Advisers estimated that the GENEROUS program will save Medicaid $64.3 billion over the next decade. AI Illustration. Upload story photo >

Live Poll

Do you trust the federal government's long-term budget savings projections for healthcare programs?

The White House Council of Economic Advisers projected $64.3 billion in Medicaid drug savings over ten years following the January 2026 launch of the GENEROUS model. Forty states and Puerto Rico joined the program, which seeks to lower costs by pegging rebates to prices paid by other nations.

Why it matters

The program aims to curb healthcare spending by leveraging most-favored-nation pricing for prescription drugs, which currently make up 6% of Medicaid expenditures. Proponents suggest this could significantly reduce the burden on state budgets, though critics have raised concerns regarding transparency.

The CEA projects $64.3 billion in savings over ten years, with states expected to retain $27.6 billion of that total. CMS estimates that annual rebates could reach $5.2 billion depending on the specific drugs states choose to include.

The players

White House Council of Economic Advisers

This agency provides the President with objective economic analysis and advice on the development and implementation of a wide range of domestic and international economic policy.

Centers for Medicare & Medicaid Services

This federal agency within the United States Department of Health and Human Services administers the nation's major healthcare programs.

President Donald Trump

He is the current President of the United States and has publicly advocated for the potential financial impact of the GENEROUS program.

FactCheck.org

This nonpartisan project monitors the factual accuracy of what is said by major U.S. political players and has reviewed the administration's savings projections.

The details

Under the GENEROUS program, drugmakers pay states rebates tied to pricing structures used in other countries, with states selecting which medications to include. The CEA model assumes that current U.S. Medicaid prices are 2.5 times higher than the international reference prices used for the rebate calculations.

The GENEROUS model program launched in January 2026.
In fiscal 2024, states spent $325 billion on Medicaid.
On September 18, 2026, President Trump stated savings could reach $100 billion.
The deadline for states to sign GENEROUS agreements was September 30, 2026.
FactCheck.org published a review of the savings claims on October 5, 2026.

Market Landscape

The GENEROUS model program marks a departure from historical Medicaid procurement by tying state rebates to international pricing benchmarks. This shift aims to consolidate state bargaining power against the existing pharmaceutical pricing landscape.

While the program targets state-level budget savings, the impact on average citizens depends on how states choose to allocate these funds. Households may see indirect benefits if the savings lead to more sustainable state-level healthcare program funding or reduced fiscal pressure.

The takeaway

The effectiveness of the GENEROUS model remains dependent on the specific drug selections made by individual states. Observers note that while the projected savings are substantial, achieving them requires long-term adherence to international pricing models that differ significantly from historical norms.